



# HHS Public Access

Author manuscript

*Angew Chem Int Ed Engl.* Author manuscript; available in PMC 2018 October 09.

Published in final edited form as:

*Angew Chem Int Ed Engl.* 2017 October 09; 56(42): 13006–13010. doi:10.1002/anie.201707274.

## Synthesis of [<sup>18</sup>F]Fluoroarenes via Nucleophilic Radiofluorination of *N*-Arylsydnone

**Dr. Maruthi Kumar Narayanam,**

Department of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 (USA)

**Dr. Gaoyuan Ma,**

Department of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 (USA)

**Dr. Pier Alexandre Champagne,**

Department of Chemistry and Biochemistry, and Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095 (USA)

**Prof. K. N. Houk, and**

Department of Chemistry and Biochemistry, and Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095 (USA)

**Prof. Jennifer M. Murphy**

Department of Molecular and Medical Pharmacology and Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 (USA)

### Abstract

A practical method for radiofluorination of anilines with [<sup>18</sup>F]fluoride via *N*-arylsydnone intermediates is described. These precursors are stable, easy to handle and facilitate direct and regioselective <sup>18</sup>F-labeling to prepare [<sup>18</sup>F]fluoroarenes. The value of this methodology is further highlighted by successful application to prepare an <sup>18</sup>F-labeled neuropeptide.


### TOC image

A practical radiofluorination of anilines with [<sup>18</sup>F]fluoride is achieved via *N*-arylsydnone intermediates. This method displays broad functional group tolerance, is compatible to automation on a commercial radiosynthesis module and can facilitate rapid <sup>18</sup>F-labeling of peptides.

---

Correspondence to: Jennifer M. Murphy.

Supporting information for this article is given via a link at the end of the document.



## Keywords

fluorine-18; fluoroarene; sydnone; click chemistry; peptide radiolabeling

Positron emission tomography (PET) is emerging as a critically important, non-invasive in vivo imaging technique used for diagnosing, staging and therapy monitoring of disease.<sup>[1]</sup> The convenient half-life (110 min), high positron yield (97%), and broad availability of fluorine-18 (<sup>18</sup>F) continue to make it the preferred radionuclide for clinical PET.<sup>[2]</sup> For decades the landscape of molecules easily accessible for widespread PET research has been limited by chemistry. Early approaches to afford [<sup>18</sup>F]fluoroarenes from [<sup>18</sup>F]fluoride were based on the Balz-Schiemann reaction via aryldiazonium salts.<sup>[3]</sup> Poor yields, competing fluoride incorporation from the BF<sub>4</sub><sup>-</sup> counterion, and precursor instability has impeded wide adoption of this methodology for <sup>18</sup>F radiotracer preparation.<sup>[4]</sup> Recent advances in fluorination chemistry, particularly transition-metal-mediated methods to afford fluoroarenes, have soared dramatically in the last 5 years.<sup>[5]</sup> Fluorination with the radioisotope fluorine-18 has in turn significantly expanded the scope and diversity of <sup>18</sup>F-labeled small molecules.<sup>[4, 6]</sup> These metal-mediated methods offer approaches to previously inaccessible <sup>18</sup>F-labeled aromatics, thus increasing the potential radiochemical space for pre-clinical or clinical PET.<sup>[7]</sup> However, many methods rely on stoichiometric quantities of transition metals to forge the carbon-fluorine bond, require complex starting materials, or suffer from competing protonation side-reactions. Such characteristics pose practical challenges for automation on a commercial radiosynthesis platform and require difficult purification steps that affect the overall yield and reproducibility of these methods.

Despite the remarkable, recent developments in radiofluorination, <sup>18</sup>F-labeled arenes are most frequently synthesized via nucleophilic aromatic substitution (S<sub>N</sub>Ar).<sup>[4]</sup> Trimethylanilinium triflates, triarylsulfonium salts,<sup>[8]</sup> diarylsulfoxides,<sup>[9]</sup> and diarylselenones<sup>[10]</sup> are typical precursors used in S<sub>N</sub>Ar reactions (Scheme 1). Diaryliodonium salts<sup>[11]</sup> are also viable precursors which give moderate to good selectivity that can be significantly improved with a copper catalyst.<sup>[12]</sup> Alternatively, spirocyclic iodonium ylides have demonstrated regioselective <sup>18</sup>F-fluorination with a broad substrate scope.<sup>[13]</sup> Recently, a concerted S<sub>N</sub>Ar reaction was reported to enable <sup>18</sup>F-deoxyfluorination of phenols via uronium intermediates.<sup>[14]</sup> However, competing formation of volatile [<sup>18</sup>F]fluoromethane,<sup>[15]</sup> regioisomeric mixtures of <sup>18</sup>F-labeled products,<sup>[8a]</sup> challenging precursor preparation or requirement for expensive reagents can be limiting for these methods.

Sydnes are remarkably stable mesoionic heterocycles composed of an azomethine imine 1,3-dipole that, upon cycloaddition with alkynes and expulsion of CO<sub>2</sub>, afford substituted

pyrazole products.<sup>[16]</sup> From our previous experience constructing functionalized sydnone, we hypothesized that the electron-withdrawing nature of the 1,2,3-oxadiazole motif might enable activation of the attached aromatic ring for metal-free S<sub>N</sub>Ar chemistry. Arylsydnone are particularly attractive precursors for PET radiotracers as they can be readily prepared from inexpensive, commercially available anilines. Additionally, the mesoionic ring is stable to most chemical group manipulations, which allows for construction of functionally diverse precursors.

We report the development of a new method for the nucleophilic <sup>18</sup>F-fluorination of a broad range of aniline-derived *N*-arylsydnone (Scheme 1). These shelf-stable precursors can be handled in air, without special precautions, and their radiofluorination readily proceeds with [<sup>18</sup>F]fluoride, without expensive stoichiometric reagents or transition-metal catalysts. In addition, we apply this methodology towards the synthesis of a sydnone prosthetic group and demonstrate rapid and facile <sup>18</sup>F-labeling of a commercial peptide via [3+2] cycloaddition.

*N*-Arylsydnone are prepared in two steps from the appropriate anilines via initial formation of *N*-aryl glycines (Scheme 2).<sup>[17]</sup> Subsequent *N*-nitrosation and cyclodehydration of the resulting nitrosamines affords the mesoionic compounds in good yields.

We initially investigated <sup>18</sup>F-fluorination of 4-nitro-phenyl sydnone **4** because of the strongly activating nature of *para*-nitro substituents for S<sub>N</sub>Ar reactions. Radiofluorination of **4** proceeded in excellent radiochemical conversion (RCC) to afford [<sup>18</sup>F]fluoro-4-nitrobenzene **4a** after 5 min at 150 °C (Scheme 3). *Ortho* substitution was well tolerated, affording **5a** – **7a** in >92% RCC. For **5** and **6**, radiofluorination can also proceed at mild temperature (70 °C) in 68% and 72% RCC, respectively. Of note, formation of 4-[<sup>18</sup>F]fluorophenyl sydnone **4b** via displacement of the nitro group was not detected, whereas sydnone displacement occurred readily. This selectivity resulted in a single radioactive product, and very clean HPLC traces, in all cases examined.

To understand the origin of this selectivity, we performed density functional theory (DFT) calculations at the M06-2X/6-311+G(d,p) level of theory,<sup>[18]</sup> using Gaussian 09 (Figure 1).<sup>[19]</sup> The SMD solvation model<sup>[20]</sup> for DMSO was used throughout the calculations. For the reaction of **4** with fluoride, a typical S<sub>N</sub>Ar mechanism is found, whether attack of F<sup>-</sup> occurs on C(1) (sydnone-bearing) or C(4) (nitro-bearing). In both cases, a barely stable Meisenheimer σ-complex (**int**) is located after the rate-determining fluoride addition transition state (**TS1**). Addition at C(1) is predicted to be 3.9 kcal/mol more favorable than addition at C(4), which is consistent with exclusive substitution of the sydnone group from **4**.

This reactivity difference can be explained by the electronic structure of **4**. Natural bond orbital (NBO) analysis shows that C(1) bears a partial positive charge (+0.18) double in magnitude to that of C(4) (+0.07).<sup>[19b]</sup> This indicates that a sydnone is inductively more electron-withdrawing than a nitro. This also explains why the formation of **4a** is more exergonic (by 10.0 kcal/mol) than **4b**, following the elimination transition state (**TS2**).

Indeed, the sydnone anion ejected upon C(1) substitution is an excellent leaving group, much more stable than the nitrite that would result from reaction at C(4).<sup>[19b]</sup>

Although a sydnone is inductively more electron-withdrawing than a nitro, it cannot however achieve full resonance with the aromatic ring, due to unfavorable *peri* hydrogen contacts that prohibit the two groups from being coplanar. In **4**, the sydnone plane lies 40° away from the aryl plane (Figure 1), limiting its ability to stabilize an incoming negative charge by resonance delocalization. As such, we have estimated the Hammett  $\sigma_p^-$  constant<sup>[21]</sup> of sydnone (0.79)<sup>[22]</sup> to be much smaller than that of nitro (1.24).<sup>[19b]</sup> This indicates that a nitro is a better anion stabilizer than a sydnone, and its positioning *para* to the site of attack is preferred during an S<sub>N</sub>Ar reaction. Overall, fluoride addition at C(1) of **4** is strongly favored, because this pathway enjoys greater stabilizing interactions as the reaction progresses. This was confirmed by a distortion/interaction analysis along the IRC.<sup>[19b, 23]</sup>

With these results in hand, the optimized reaction conditions were applied to a series of diverse *N*-arylsydnes to establish the scope of the reaction. As summarized in Figure 2, the radiofluorination proceeds in high RCC with substrates bearing electron-withdrawing substituents on the aryl ring and is compatible with numerous functional groups, such as nitro, cyano, ester, chloro, trifluoromethyl, ether, sulfone, sulfonamide, pyrrolidinyl, morpholinyl and amide. Several heterocycles, which are often problematic for metal-mediated radiofluorination methods, underwent radiofluorination with high RCC to afford thiophene (**15a**), benzofuran (**16a**) and pyridine (**17a**) derivatives. Of particular note is the successful preparation of ethyl 3-[<sup>18</sup>F]fluorobenzofuran-2-carboxylate **16a** in 45% RCC which is, to the best of our knowledge, the first report of an [<sup>18</sup>F]benzofuran derivative. Synthesis of methyl 3-[<sup>18</sup>F]fluorothiophene-2-carboxylate **15a** in 33% RCC is also significant as thiophenes are consistently difficult to radiofluorinate.<sup>[4]</sup> Unactivated or electron rich substituents failed to give detectable [<sup>18</sup>F]fluorinated products.<sup>[19b]</sup>

While sydnes are valuable precursors for the synthesis of functionalized pyrazoles<sup>[24]</sup> and biologically interesting molecules,<sup>[16c]</sup> their most popular utility in the last few years has been their role in bioorthogonal reactions.<sup>[17b, 25]</sup> Previously, we disclosed the bioorthogonal reaction of phenyl sydnes with dibenzocyclooctyne derivatives DIBAC and BARAC to undergo [3+2] cycloaddition for applications in fluorescence protein labeling.<sup>[25c]</sup>

Encouraged by these results, we sought to utilize this ligation to rapidly incorporate [<sup>18</sup>F]fluorine into peptides and other biomolecules for applications in PET molecular imaging. Thus, we applied our radiofluorination method towards the synthesis of 4-[<sup>18</sup>F]fluorophenyl sydnone **4b** via the phenyl bissydnone precursor **21** and optimized the fully automated process using an ELIXYS radiosynthesis module (Tables S3 and S4). Unlike prosthetic groups such as [<sup>18</sup>F]fluoroethylazide and PEGylated counterparts,<sup>[26]</sup> sydnone **4b** is stable, non-volatile and displays strong UV absorbance. These properties make isolation and handling significantly less challenging and also simplify identification and quantification of the radiolabeled product via HPLC analysis.

Using **4b** as a prosthetic group, we radiolabeled the 5 amino acid (H-Tyr-Ala-Gly-Phe-Leu-OH) neuropeptide, [D-Ala<sup>2</sup>, D-Leu<sup>5</sup>]-Enkephalin **23** (Scheme 4). Peptide **23** is a selective

delta-opioid receptor agonist which displays protective effects towards the preservation of neurologic function and neuronal damage against hypoxic or ischemic induced brain injury.<sup>[27]</sup> Peptide **23** was functionalized with succinimidyl ester **22** to afford DIBAC-peptide conjugate **24**. The desired 4-<sup>[18F]</sup>fluorophenyl sydnone **4b** (6–10 mCi) was purified and isolated within 62 min from the end of bombardment in 21 ± 3% non-decay-corrected radiochemical yield (RCY) (n=17) with a specific activity of 1.3 Ci μmol<sup>-1</sup>. Purified **4b** was stirred with **24** in 1:1 DMSO:PBS at a concentration typically reported for <sup>[18F]</sup>peptide labeling.<sup>[28]</sup> Remarkably, clean conversion (>97%) to pyrazole **25** was observed after 15 min at 40 °C, as determined by HPLC analysis of the reaction mixture (Figures S24 and S25). Notably, in all cases investigated, cycloaddition with **4b** proceeded at 37 °C to >98% conversion after 30 min; at 50 °C, complete conversion was achieved within 8 min (Table S6).<sup>[19b]</sup> Our application of <sup>[18F]</sup>sydnones as bioorthogonal prosthetic groups for the production of <sup>18F</sup> radiotracers is related to Taran and coworkers' recent Pd(II)-mediated formation of 4-<sup>[18F]</sup>fluoro-*N*-(*p*-tolyl)-sydnone, which is also an efficient cycloaddition partner.<sup>[29]</sup> Indeed, our method compares advantageously as it uses simple reagents for one-step, direct radiofluorination without transition metals, gives improved RCY and is fully automatable.

In conclusion, the first practical nucleophilic radiofluorination of anilines with <sup>[18F]</sup>fluoride is achieved by the initial modification of ArNH<sub>2</sub> to an *N*-arylsydnone precursor via a two-step process. This simple transformation was successfully automated on a commercial radiochemistry synthesis module to provide an efficient synthesis of 4-<sup>[18F]</sup>fluorophenyl sydnone which was utilized to prepare an <sup>18F</sup>-labeled neuropeptide via bioorthogonal cycloaddition. We anticipate this methodology will complement the expanding radiofluorination methods and, due to its operational simplicity, find extensive applications in the production of radiopharmaceuticals for PET molecular imaging.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This work was supported by the Jonsson Comprehensive Cancer Center Seed Grant, the Crump Institute for Molecular Imaging, the NIH (R01GM109078) and the FRQNT (postdoctoral fellowship to P.A.C.).

## References

1. a) Weber WA, Grosu AL, Czernin J. *Nat Clin Pract Oncol*. 2008; 5:160–170. [PubMed: 18253106]  
b) Ametamey SM, Honer M, Schubiger PA. *Chem Rev*. 2008; 108:1501–1516. [PubMed: 18426240]
2. a) Fowler JS, Wolf AP. *Acc Chem Res*. 1997; 30:181–188. b) Phelps ME. *Proc Natl Acad Sci USA*. 2000; 97:9226–9233. [PubMed: 10922074] c) Cai L, Lu S, Pike VW. *Eur J Org Chem*. 2008; 2008:2853–2873. d) Miller PW, Long NJ, Vilar R, Gee AD. *Angew Chem Int Ed*. 2008; 47:8998–9033. *Angew Chem*. 2008; 120:9136–9172. e) Littich R, Scott PJH. *Angew Chem Int Ed*. 2012; 51:1106–1109. *Angew Chem*. 2012; 124:1132–1135.
3. Nozaki T, Tanaka Y. *Int J Appl Radiat Isot*. 1967; 18:111–119.
4. Preshlock S, Tredwell M, Gouverneur V. *Chem Rev*. 2016; 116:719–766. [PubMed: 26751274]


5. a) Brown JM, Gouverneur V. *Angew Chem Int Ed*. 2009; 48:8610–8614. *Angew Chem*. 2009; 121:8762–8766. b) Watson DA, Su M, Teverovskiy G, Zhang Y, García-Fortanet J, Kinzel T, Buchwald SL. *Science*. 2009; 325:1661–1664. [PubMed: 19679769] c) Mazzotti AR, Campbell MG, Tang P, Murphy JM, Ritter T. *J Am Chem Soc*. 2013; 135:14012–14015. [PubMed: 24040932] d) Ye Y, Sanford MS. *J Am Chem Soc*. 2013; 135:4648–4651. [PubMed: 23485148] e) Fier PS, Hartwig JF. *Science*. 2013; 342:956–960. [PubMed: 24264986] f) Ye Y, Schimler SD, Hanley PS, Sanford MS. *J Am Chem Soc*. 2013; 135:16292–16295. [PubMed: 24160267] g) Fier PS, Luo J, Hartwig JF. *J Am Chem Soc*. 2013; 135:2552–2559. [PubMed: 23384209] h) Campbell MG, Ritter T. *Chem Rev*. 2015; 115:612–633. [PubMed: 25474722] i) Gamache RF, Waldmann C, Murphy JM. *Org Lett*. 2016; 18:4522–4525. [PubMed: 27571319]
6. a) Lee E, Hooker JM, Ritter T. *J Am Chem Soc*. 2012; 134:17456–17458. [PubMed: 23061667] b) Brooks AF, Topczewski JJ, Ichiishi N, Sanford MS, Scott PJH. *Chem Sci*. 2014; 5:4545–4553. [PubMed: 25379166] c) Tredwell M, Preshlock SM, Taylor NJ, Gruber S, Huihan M, Passchier J, Mercier J, Génicot C, Gouverneur V. *Angew Chem Int Ed*. 2014; 53:7751–7755. *Angew Chem*. 2014; 126:7885–7889. d) Mossine AV, Brooks AF, Makaravage KJ, Miller JM, Ichiishi N, Sanford MS, Scott PJH. *Org Lett*. 2015; 17:5780–5783. [PubMed: 26568457] e) Makaravage KJ, Brooks AF, Mossine AV, Sanford MS, Scott PJH. *Org Lett*. 2016; 18:5440–5443.
7. a) Kamlet AS, Neumann CN, Lee E, Carlin SM, Moseley CK, Stephenson N, Hooker JM, Ritter T. *PLoS One*. 2013; 8:e59187. [PubMed: 23554994] b) Ren H, Wey HY, Strebl M, Neelamegam R, Ritter T, Hooker JM. *ACS Chem Neurosci*. 2014; 5:611–615. [PubMed: 24845956] c) Zlatopolskiy BD, Zischler J, Krapf P, Zarrad F, Urusova EA, Kordys E, Endepols H, Neumaier B. *Chem Eur J*. 2015; 21:5972–5979. [PubMed: 25708748] d) Hoover AJ, Lazari M, Ren H, Narayanan MK, Murphy JM, van Dam RM, Hooker JM, Ritter T. *Organometallics*. 2016; 35:1008–1014. [PubMed: 27087736] e) Preshlock S, et al. *Chem Commun*. 2016; 52:8361–8364. f) Zischler J, Kolks N, Modemann D, Neumaier B, Zlatopolskiy BD. *Chem Eur J*. 2017; 23:3251–3256. [PubMed: 27943464]
8. a) Mu L, et al. *Eur J Org Chem*. 2012; 2012:889–892. b) Sander K, Gendron T, Yiannaki E, Cybulska K, Kalber TL, Lythgoe MF, Årstad E. *Sci Rep*. 2015; 5:9941. [PubMed: 25898175]
9. Chun JH, Morse CL, Chin FT, Pike VW. *Chem Commun*. 2013; 49:2151–2153.
10. Siméon FG, Lu S, Pike VW. *J Label Compd Radiopharm*. 2015; 58(Suppl1):S1.
11. a) Pike VW, Aigbirhio FI. *J Chem Soc Chem Commun*. 1995:2215–2216. b) Ross TL, Ermert J, Hocke C, Coenen HH. *J Am Chem Soc*. 2007; 129:8018–8025. [PubMed: 17536798] c) Yusubov MS, Svitich DY, Larkina MS, Zhdankin VV. *ARKIVOC*. 2013:364–395.
12. Ichiishi N, Brooks AF, Topczewski JJ, Rodnick ME, Sanford MS, Scott PJH. *Org Lett*. 2014; 16:3224–3227. [PubMed: 24890658]
13. a) Rotstein BH, Stephenson NA, Vasdev N, Liang SH. *Nat Commun*. 2014; 5:4365. [PubMed: 25007318] b) Rotstein BH, Wang L, Liu RY, Patteson J, Kwan EE, Vasdev N, Liang SH. *Chem Sci*. 2016; 7:4407–4417. [PubMed: 27540460]
14. Neumann CN, Hooker JM, Ritter T. *Nature*. 2016; 534:369–373. [PubMed: 27281221]
15. Sun H, DiMugno SG. *J Fluorine Chem*. 2007; 128:806–812.
16. a) Earl JC, Mackney AW. *J Chem Soc*. 1935:899–900. b) Huisgen R, Grashey R, Gotthardt H, Schmidt R. *Angew Chem Int Ed*. 1962; 1:48–49. *Angew Chem*. 1962; 74:29–30. c) Browne DL, Harrity JPA. *Tetrahedron*. 2010; 66:553–568.
17. a) Specklin S, Decuypere E, Plougastel L, Aliani S, Taran F. *J Org Chem*. 2014; 79:7772–7777. [PubMed: 25054615] b) Plougastel L, Koniev O, Specklin S, Decuypere E, Creminon C, Buisson DA, Wagner A, Kolodych S, Taran F. *Chem Commun*. 2014; 50:9376–9378. c) Fang Y, Wu C, Larock RC, Shi F. *J Org Chem*. 2011; 76:8840–8851. [PubMed: 21970468]
18. Zhao Y, Truhlar DG. *Theor Chem Acc*. 2008; 120:215–241.
19. Frisch, MJ., et al. *Gaussian 09, Revision D.01*. Gaussian, Inc.; Wallingford CT: 2013. b) See the Supporting Information file for details
20. Marenich AV, Cramer CJ, Truhlar DG. *J Phys Chem B*. 2009; 113:6378–6396. [PubMed: 19366259]
21. Hansch, C., Leo, A. *Substituent constants for correlation analysis in chemistry and biology*. Vol. vii. Wiley; New York: 1979. p. 339

22. Our computational estimation closely resembles the experimentally-measured value of 0.71; see: Tin-Lok C, Miller J, Stansfield F. *J Chem Soc.* 1964:1213–1216.
23. a) Ess DH, Houk KN. *J Am Chem Soc.* 2007; 129:10646–10647. [PubMed: 17685614] b) Ess DH, Houk KN. *J Am Chem Soc.* 2008; 130:10187–10198. [PubMed: 18613669] c) van Zeist WJ, Bickelhaupt FM. *Org Biomol Chem.* 2010; 8:3118–3127. [PubMed: 20490400] d) Yang YF, Liang Y, Liu F, Houk KN. *J Am Chem Soc.* 2016; 138:1660–1667. [PubMed: 26804318] e) Fell JS, Martin BN, Houk KN. *J Org Chem.* 2017; 82:1912–1919. [PubMed: 28150495] f) Bickelhaupt FM, Houk KN. *Angew Chem Int Ed.* 2017; 56 [dx.doi.org/10.1002/anie.201701486](https://doi.org/10.1002/anie.201701486).
24. a) Decuypere E, Specklin S, Gabillet S, Audisio D, Liu H, Plougastel L, Kolodych S, Taran F. *Org Lett.* 2015; 17:362–365. [PubMed: 25545588] b) Browne DL, Helm MD, Plant A, Harrity JPA. *Angew Chem Int Ed.* 2007; 46:8656–8658. *Angew Chem.* 2007; 119:8810–8812. c) Foster RS, Adams H, Jakobi H, Harrity JPA. *J Org Chem.* 2013; 78:4049–4064. [PubMed: 23548035]
25. a) Kolodych S, Rasolofonjatovo E, Chaumontet M, Nevers MC, Créminon C, Taran F. *Angew Chem Int Ed.* 2013; 52:12056–12060. *Angew Chem.* 2013; 125:12278–12282. b) Wallace S, Chin JW. *Chem Sci.* 2014; 5:1742–1744. [PubMed: 25580211] c) Narayanam MK, Liang Y, Houk KN, Murphy JM. *Chem Sci.* 2016; 7:1257–1261.
26. Pretze M, Pietzsch D, Mamat C. *Molecules.* 2013; 18:8618–8665. [PubMed: 23881051]
27. a) Liu H, Chen B, Zhang Y, Qiu Y, Xia Y, Li S, Yao J. *Neurosci Lett.* 2015; 584:1–6. [PubMed: 25283992] b) Fu D, Liu H, Zhu H, Li S, Yao J. *Neuroreport.* 2016; 27:749–754. [PubMed: 27232517]
28. a) Hausner SH, Carpenter RD, Bauer N, Sutcliffe JL. *Nucl Med Biol.* 2013; 40:233–239. [PubMed: 23265667] b) Chiotellis A, Sladojevich F, Mu L, Muller Herde A, Valverde IE, Tolmachev V, Schibli R, Ametamey SM, Mindt TL. *Chem Commun.* 2016; 52:6083–6086.
29. Liu H, et al. *Angew Chem Int Ed.* 2016; 55:12073–12077. *Angew Chem.* 2016; 128:12252–12256.




**Figure 1.** Calculated free energy profile for addition of fluoride to either C(1) (pathway a, in red) or C(4) (pathway b, in blue) of **4** (M06-2X/6-311+G(d,p)/SMD(DMSO) level of theory).




**Figure 2.**


Scope of sydnone-mediated  $^{18}\text{F}$  fluorination. Reaction conditions: precursor (25  $\mu\text{mol}$ ),  $\text{Et}_4\text{NHCO}_3$  (50  $\mu\text{mol}$ ), DMSO (200  $\mu\text{L}$ ), [ $^{18}\text{F}$ ]fluoride (300  $\mu\text{Ci}$ ), 150  $^\circ\text{C}$ , 5 min. RCC was determined by radio-TLC. The identity of each labeled product was confirmed by radio-HPLC; <sup>a</sup>10 min. <sup>b</sup>15 min. <sup>c</sup>20 min. <sup>d</sup>RCC reported as radio-TLC conversion multiplied by radio-HPLC fraction of identified product.

**Scheme 1.**


Modern, metal-free methods for  $^{18}\text{F}$  fluorination of arenes.

**Scheme 2.**

Preparation of *N*-arylsydnone precursors. Reagents and conditions: (a) ethyl bromoacetate, NaOAc, EtOH, reflux; LiOH, H<sub>2</sub>O:THF (1:1), 0 °C; (b) NaOAc, AcOH, glyoxylic acid monohydrate, NaBH<sub>3</sub>CN, MeOH, RT; (c) *t*-Butyl nitrite, THF, trifluoroacetic anhydride, RT. THF = tetrahydrofuran.

**Scheme 3.**

Radiofluorination of *para*-nitro substituted *N*-arylsydnonones. RCC was determined by radio-TLC. <sup>a</sup>n = 4. <sup>b</sup>n = 3. DMSO = dimethyl sulfoxide.

**Scheme 4.**

Preparation and application of [ $^{18}\text{F}$ ]sydnone **4b** towards  $^{18}\text{F}$  labelling of peptide [D-Ala<sup>2</sup>, D-Leu<sup>5</sup>]-Enkephalin **23**.